High Expression of TGF-β1 Contributes to Hepatocellular Carcinoma Prognosis via Regulating Tumor Immunity

Xiuli Jin1, Shuairan Zhang2, Ningning Wang1, Lin Guan1, Chuanli Shao3, Yingbo Lin4, Jianping Liu5* and Yiling Li1*

1 Department of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, China, 2 Department of Medical Oncology, First Affiliated Hospital of China Medical University, Shenyang, China, 3 Emergency Department, Bengbu First People’s Hospital, Bengbu, China, 4 Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden, 5 Department of Gastroenterology, First Affiliated Hospital of Nanchang University, Nanchang, China

Background: Transforming growth factor-beta (TGF-β) signaling is essential in initialization and progression of hepatocellular carcinoma (HCC). Therefore, a treatment targeting TGF-β pathway may be a promising option for HCC control.

Methods: First, publicly available RNA-seq datasets and clinical characteristics of 374 HCC patients in The Cancer Genome Atlas (TCGA) database were downloaded. Then, Cox regression analysis and LASSO analysis were used to construct a prognostic model for TGF-β family genes. The area under the curve (AUC) of the risk signature was calculated to evaluate the predictive power of the model. Cox regression analysis was applied to predict whether TGF-β1 can be an independent prognosis factor for HCC. Next, hazard ratio and survival analyses were performed to investigate the correlation between TGF-β1 expression and survival time. Furthermore, differential expression level of TGF-β1 in HCC tissues and cells was determined. In addition, Gene Set Enrichment Analysis (GSEA) identified the top significantly activated and inhibited signal pathways related to high expression of TGF-β1. Finally, the CIBERSORT tool was adopted to correlate the tumor-infiltrating immune cells (TICs) with TGF-β1 expression in HCC cohorts.

Results: Cox regression analysis and LASSO analysis revealed that seven TGF-β family members (including TGF-β1) could be used as prognostic factors for HCC. Interestingly, TGF-β1 was demonstrated to be an independent prognostic factor of HCC. RT-qPCR and immunofluorescence staining confirmed the high expression of TGF-β1 in HCC cell lines and tissues, which is significantly related to pathological classifications, poor prognosis, and short survival time. Finally, GSEA and CIBERSORT analyses suggested that TGF-β1 may interact with various immune cells and influence the prognosis of HCC patients through Tregs and γδ T cells.

Conclusion: We established a novel prognostic prediction method to predict the risk scores of TGF-β genes in HCC prognosis. TGF-β1 is highly expressed in HCC cell lines.
INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide, especially in developing countries (1). Despite the development of multi-modal and advanced therapeutics, including surgical approaches and systemic drug treatment, the overall survival of HCC patients remains rather poor (2). Aided by the in-depth study of the tumor microenvironment (TME), immunotherapy has become a promising treatment for HCC patients (3, 4). However, the complexity of TME highlights the presence of multiple non-redundant mechanisms of cancer immune-suppression, which is recognized as a critical barrier against immunotherapy (5). Consequently, identification of fundamental target genes and signaling pathways that are related to immunotherapy in HCC is imperative for developing novel HCC therapeutic agents.

Transforming growth factor beta (TGF-β) is a family of cytokines and growth factors encoded by 32 genes, which can be divided into two groups, represented by TGF-βs and bone morphogenic proteins (BMPs) (6). TGF-β, the prototypical member of the TGF-β family, consists of three isoforms in mammals (TGF-β1, TGF-β2, and TGF-β3), among which TGF-β1 is the most abundant and well-studied family member (7). TGF-β and the TGF-β signal pathway, in orchestration with many other important genes and pathways, play central roles in various cancer initialization, progression, and treatment (8). First, TGF-β expression is significantly increased through cancer progression, which is often correlated to a poor prognosis (9). TGF-β signaling is involved in all the stages of liver disease progression from initial liver injury to development of HCC (10). Then, TGF-β can drive changes in immune cells to induce a strong immune-suppressive milieu (11). Meanwhile, TGF-β may trigger the signals in a paracrine manner to promote tumor progression in the TME (12, 13).

As a highly complicated system, the TME is composed of various cell types and molecules, including tumor cells, infiltrating immune cells, cancer-associated stromal cells, endothelial cells, and lipocytes, along with some extracellular matrix (ECM) and multiple signaling molecules (14, 15). The tumor immune microenvironment (TIME) is a novel concept that is closely related to the clinical prognosis of patients with tumors (16). The proportions of immunosuppressive cells such as M2-type macrophages, regulatory T (Treg) cells, and myeloid-derived suppressor cells (MDSCs), which are modified by CAFs (cancer-associated fibroblasts), have been shown to be significantly increased in the TIME, thereby contributing to tumor immune suppression (17-19). Accumulating evidence has shown that TGF-β signaling is involved in the regulation of immunosuppressive microenvironment (6, 20, 21).

In the present study, using various bioinformatic approaches, RT-qPCR and immunofluorescence staining techniques, we analyzed the correlation between TGF-β gene family and HCC progression, with the focus on TGF-β1. We aim to explore the possibility of utilizing TGF-β1 as a potential marker for immunotherapy and prognostic evaluation of HCC. Finally, we found that TGF-β1 is abnormally highly expressed and related to immune cells in HCC samples, which may provide new insights for early diagnosis and immunotherapy of HCC.

MATERIALS AND METHODS

Extraction of HCC RNA-seq Data from TCGA

RNA-seq FPKM (Fragments Per Kilobase of transcript per Million mapped reads) datasets of 374 HCC patients including 50 para-cancerous samples, and the clinical information were downloaded from The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC, www.portal.gdc.cancer.gov).

Bioinformatic Tools Used in This Study

R package was installed through Rstudio (version 4.12). The following packages or software were used for downstream analyses: beeswarm (v 0.4.0), CIBERSORT (v 1.03), corplot (v 0.92), e1071 (v 1.7-9), forestplot (v 2.0.1), ggplot (v 2.3.3), ggpubr (v 0.4.0), ggextra (v 3.6.2), GSEA (v 4.10), limma (v 3.48.3), Parallel (stage 4), Preprocesscore (v 1.54.0), survival (v 3.2-13), survminer (v 0.4.9), tidyverse (v 1.3.1), timeROC (v 0.4), and vioplot (v 0.3.7).

Construction of the Prognostic Model for TGF-β-Related Genes

Thirty-two TGF-β-related genes were selected according to the previous studies (22-24). Expression data of the 32 genes were extracted and correlated with the survival information. Univariate Cox regression analyses were performed based on the pre-processed data. Hazard ratio (HR) was computed using the survival, survminer, and forestplot packages. To avoid overfitting of the model, least absolute shrinkage and selection operator (LASSO) regression was applied to reduce model dimension, and the optimal lambda values were computed for each significant gene.
Validation of the Prognostic Model for TGF-β-Related Genes

Risk value was calculated for each HCC patient based on the coefficient using the following formula:

\[
RiskScore = \sum_{i=1}^{n} coef(gene_i) \times exp(gene_i)
\]

Taking the median of the risk value as a cutoff, the HCC patients were divided into high- and low-risk groups for risk score calculation and survival analysis. Receiver operating characteristic (ROC) curves for 1-, 3-, and 5-year survival time were plotted, with the area under curve (AUC) calculated to illustrate the prognostic capability of TGF-β related genes in HCC progression.

GSEA, GO, and Immune Infiltration Analysis Based on TGF-β1 Expression

Based on the TGF-β1 expression of the HCC patients, we performed differential expression analysis, survival analysis, clinical association analysis, and prognosis analysis using multiple R packages. First, GSEA (Gene Set Enrichment Analysis) was carried out against KEGG (Kyoto Encyclopedia of Genes and Genomes) database to analyze the differential activation of signal pathways between TGF-β1 high cohort and TGF-β1 low group. NES (normalized enrichment score) >2, and \( p \)-value and adjusted \( p \)-value < 0.01 were considered as significant. Similarly, Gene Ontology (GO) enrichment was performed to compare the difference in biological processes, cellular components, and molecular functions between the two groups. \(|\log_{2}\text{FoldChange}| > 1 \) and \( p < 0.05 \) were considered as significant. Then, immune infiltration analysis was conducted using CIBERSORT to compute the percentage of the 22 types of immune cells in each HCC sample and correlated to its TGF-β1 expression.

Cell Culture

Human fetal hepatocyte cell line LO2 and liver HCC cell lines (HepG2 and Huh7) were purchased from Cell Bank of Chinese Academy of Sciences and tested to be mycoplasma negative (LookOut® Mycoplasma PCR Detection Kit, Cat. No.: MP0035, Sigma-Aldrich) prior to this study. After identity confirmation using Goldeneye™ 20A STR complex Amplification Kit (Goldeneye Ltd, Beijing, China), the cells were grown to approximate 80% confluence in Dulbecco’s modified Eagle’s medium with high glucose (HyClone) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin and streptomycin at 37°C and 5% CO₂.

Tissues from HCC Patients

Eighteen pairs of HCC and adjacent para-cancerous tissues were collected from patients with their consent at the Department of Hepatobiliary Surgery, the First Affiliated Hospital of China Medical University between May 2018 and April 2019. The sample collection was approved by the research ethics committee of First Affiliated Hospital of China Medical University. All collected samples were immediately frozen in liquid nitrogen and transferred to a −80° freezer until further analyses.

RNA Extraction and RT-qPCR

Total RNAs from fifteen pairs of frozen tissues and three cell lines were extracted using TRIzol reagent (Invitrogen), followed by cDNA synthesis using the PrimeScript RT Reagent Kit (TaKaRa). The SYBR Prime Script RT-PCR kit (TaKaRa) was used for RT-qPCR according to the manufacturer’s protocol. The relative expression was calculated using the \( \Delta\Delta^{Ct} \) method. β-ACTIN served as an internal control. The following two pairs of primer sets are used: TGFBI-F, 5'-CAACGAGTACACAGCAT-3' and TGFBI-R, 5'-TGCTCCACTTTTAACTTGAGCC-3'; ACTB-F, 5'-ATGTGGGCGAGCTTTGATT-3' and ACTB-R, 5'-AGTGGGTTGCTTTTAGGATG-3'.

Immunofluorescence Staining

Each specimen was fixed with 10% formalin, dehydrated, and embedded in paraffin. Paraffin section was 4 μm thick on glass slide. Firstly, the sections were permeabilized with 100 μl of 0.5% Triton X-100 at room temperature for 10–15 min. Then, sections were washed three times with PBS (phosphate-buffered saline). Second, the sections were washed once with 1% BSA, followed by blocking with 5% BSA. Then, the sections were incubated with primary antibody against TGF-β1(1:100; proteintech, #21898-1-AP) at 4°C overnight. Next, the sections were washed three times with PBS in a shaker, each time for 5 min. Subsequently, a secondary goat anti-rabbit antibody (1:100, proteintech, #SA00013-2) was applied to the slides at room temperature for 2 h, followed by washing three times with PBS in a shaker, each time for 5 min. Furthermore, nuclei was counter-stained using DAPI (1:1000) for 10 min, followed by washing three times with PBS in a shaker, each time for 5 min. Finally, the sections were subjected to image acquisition at confocal microscopy (Nikon, A1R).

Statistical Analyses

The charts, forest plots, and calibration plots were visualized and statistically analyzed using SPSS (version 22.0) and R (4.12). Univariate Cox regression analysis, LASSO regression analysis, and Spearman correlation coefficient were used to calculate the risk scores for the selected TGF-β1 genes, as the independent prognosis factors for HCC. Survival curves were generated using the Kaplan–Meier method. Univariate and multi-variant Cox regression analyses were adopted to predict the correlation between the selected gene and survival prognosis. Statistical differences were computed by independent \( t \) test between two groups, \( p < 0.05 \) was considered statistically significant.

RESULTS

TGF-β Family Genes as Prognostic Factors for HCC Progression

First, detailed clinical and follow-up information (gender, age, histological grade, pathologic stage, TNM stage, and
prognosis) of the 374 HCC samples were downloaded from the TCGA platform and compiled in Supplementary Table 1. Higher grade (1-4) or higher stage (1-4) indicates more malignant. TNM stands for tumor node metastasis, where T (T1-T4) implies tumor size, N suggests the existence, localization, and number of lymph node, while M means metastasis.

Next, to understand the risk signature of 32 TGF-β related genes in HCC progression, we analyzed the correlation between the expression levels of the 32 genes in HCC patients with HCC progression. Univariate Cox analysis (Figure 1A) predicted that 7 out of the analyzed 32 TGF-β related genes are significantly correlated with HCC progression ($p < 0.05$).

Then, for a more accurate prediction, LASSO regression was used to calculate the optimal lambda values (Figure 1B) and the coefficient for each gene (Figure 1C). Taken together, seven TGF-β family members (TGF-B1, LEFTY2, BMP2, BMP6, GDF6, GDF7, and GDF10) were identified as independent prognostic factors for HCC.

Finally, according to the median risk score, the cohort of patients from TCGA database was divided into high-risk and low-risk groups (Supplementary Figure 1A). The high-risk group exhibited a higher frequency of poor overall survival (OS) than the low-risk group, as shown by the survival time (Supplementary Figure 1B) and Kaplan–Meier survival curve (Figure 2A). Principal component analysis (PCA) revealed that...
these two groups had tendency towards opposite directions (Supplementary Figure 1C), confirming the validity of the prediction model, which was further supported by the AUC analysis of 1-, 3-, and 5-year survival time (Figure 2B). Therefore, we conclude that some of the TGF-β family genes can be used as prognostic factors for HCC progression.

**TGF-β1 as a Prognostic Factor for HCC Progression**

By correlating each single factor with survival time of each patient, Univariate Cox regression analysis (Figure 3A) showed that four factors (stage, T, M, and TGF-β1) are potential prognostic factors of clinical relevance and significance \( p < 0.05 \). However, HCC prognosis is not significantly related with age, gender, grade, or node \( p > 0.05 \). Furthermore, multivariate Cox regression analysis (Figure 3B) demonstrated that TGF-β1 could be an independent prognostic factor of HCC, with \( p = 0.02 \). Taken together, Cox regression analyses suggested that expression level of TGF-β1 is closely related to HCC progression.

**High TGF-β1 Expression in HCC Tissues With Poor Survival Time**

To further validate the correlation of TGF-β1 expression level with HCC prognosis, we first implemented some bioinformatic tools including limma, beeswarm, ggpubr, and tidyverse to analyze the RNA-seq data (FPKM) of the HCC tissues extracted from the TCGA database. Differential expression scatter plot (Figure 4A) revealed high TGF-β1 expression in HCC samples when compared with normal liver tissue samples, which was confirmed by the paired differential analysis (Figure 4B) using the 50 pairs of HCC tissues and the corresponding neighboring non-tumorous liver tissues.

Next, clinical correlation analysis (Figure 4C) showed that TGF-β1 expression increased along with the HCC progression through different grades, indicating poor differentiation and prognosis when TGF-β1 expression is high. However, only statistical significance was observed when comparing the data from grade 1 with that from grade 3. Furthermore, Kaplan–Meier survival curve analysis demonstrated that high TGF-β1 expression level is significantly correlated with poor survival time (Figure 4D).

Finally, in agreement with the above elaborated bioinformatic analyses, molecular and cellular evidence showed higher mRNA expression of TGF-β1 in two human HCC cell lines (Huh7 and HepG2) than in the normal human hepatic cell line (LO2) (Figure 5A) and in HCC tissues than in the corresponding paired non-tumorous liver tissues (Figure 5B), which was confirmed by immunofluorescent staining at protein level, with TGF-β1 expressed in cytoplasm (Figure 5C).

**Involvement of TGF-β1 in Immune-Associated Pathways**

To explore the underlying molecular mechanisms of TGF-β1 in HCC progression and prognosis, Gene Oncology (GO) enrichment and Gene Set Enrichment Analysis (GSEA) were performed against the KEGG database using the extracted TCGA-LIHC RNA-seq data. As shown in Figure 6A, most of the significantly enriched biological processes (BP), cellular components (CC), and molecular functions (MF) are immune related, such as humoral immune response, immunoglobulin complex, and antigen binding. These observations from GO enrichment analysis were confirmed by GSEA (Figure 6B), which revealed that many pathways were activated by high expression of TGF-β1. Out of the top 50 activated pathways, 10 are enriched in and related to immunity and cancer, as shown in Figure 6B, including B cell receptor signal pathway, natural killer cell-mediated cytotoxicity, and T cell

![FIGURE 3](image-url) | TGF-β1 expression is a prognostic factor for HCC progression. Univariate Cox regression analysis (A) and multivariate Cox regression (B) demonstrated that TGF-β1 could be a prognostic factor of HCC. Hazard ratio was computed using survival, survminer, and forestplot packages. HR, hazard ratio; CI, confidence intervals; T, tumor; M, metastasis; N, (lymph) node. \( p < 0.05 \), \( p < 0.01 \), and \( p < 0.001 \) suggest significance, strong significance, and extremely strong significance, respectively.
receptor signaling pathway. On the other hand, only 12 pathways were found to be significantly downregulated when TGF-β1 was highly expressed in HCC samples, with the first 10 pathways displayed in Figure 6B.

Then, the CIBERSORT tool from R was applied to estimate the tumor-infiltrating immune cells (TICs) for the HCC samples based on the RNA-seq datasets. Subsequently, a relationship was observed between the TGF-β1 expression and infiltration of immune cells, with the distribution percentage of 22 immune cell types from 109 HCC patients (Supplementary Table 2) shown in Figure 7. To further characterize the TICs, differential analysis of the percentage of the 22 types of immune cells in HCC patients revealed that TGF-β1 expression is positively correlated with Tregs, but negatively correlated with gd T cells (Figure 8A), as shown by the blue lines in Figures 8B, C.

**DISCUSSION**

Liver cancer is one of the most malignant tumors with high morbidity and mortality. The new cases of liver cancer in China each year account for half of the cases worldwide (1). Despite the tremendous progress achieved in surgery, liver transplantation, and radiofrequency ablation, the 5-year survival rate of HCC patients is still rather poor (25). The few and ineffective therapeutic strategies for HCC can be attributed to our poor understanding of its biology. Sorafenib, a tyrosine kinase inhibitor (TKI) to suppress the RAS/RAF/MEK/ERK signal pathway, was approved as a treatment approach for HCC. However, its efficacy is limited by the development of drug resistance and the major neuronal isoform of the pathway; furthermore, BRAF mutation in advanced HCC patients confers a multifocal and/or more aggressive behavior with TKI resistance (26), which altogether urges for more effective alternatives.

Immunotherapy is a novel systemic treatment approach for enhancement of the anti-tumor immune response of HCC patients, which has the potential to reduce tumor recurrence and metastasis (27). TGF-β signaling can promote tumor progression through immunosuppression (6, 28–30), while TGF-β1 can directly suppress immunosurveillance by inhibiting the anti-tumor activity of infiltrating immune cells and subsequently facilitating the recruitment and sustenance of protumoral immune cells to enhance metastatic progression (20).
In the current study, we employed a flora of bioinformatic packages to assess the clinical prognosis value of TGF-β signaling family in the prediction of HCC progression. Thirty-two TGF-β related genes (ACTC1, BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8A, BMP8B, BMP10, BMP15, GDF1, GDF2, GDF3, GDF5, GDF6, GDF7, GDF9, GDF10, GDF11, GDF15, GDNF, INHA, INHBA, INHBB, LEFTY2, MSTN, NRTN, PSPN, TGFBI, TGFBI, and TGFBI3) were subjected to Cox regression analysis and LASSO analysis. The prediction model showed that seven TGF-β family members (BMP2, BMP6, GDF6, GDF7, GDF10, LEFTY2, and TGFBI) could be potential independent prognostic factors for HCC, which was validated by Kaplan–Meier survival analysis and ROC analysis. Out of the seven confirmed TGF-β family members, our observation on TGF-β1 is consistently in line with previous studies (31, 32). Considering the high abundance, biological importance, and pathological relevance of TGF-β1 (33–36), we focused on TGF-β1 in this study.

Our global analyses confirmed that TGF-β1 expression is a prognosis factor for HCC progression (Figure 3). High TGF-β1 expression was noticed in HCC tissues, with poor survival time (Figure 4). In addition, experimental tools revealed that TGF-β1 is highly expressed in HCC tissue and cell lines, compared with the neighboring non-tumorous tissue from the same HCC patients and normal liver cell line (Figure 5).

Furthermore, our data showed that TGF-β1 is closely correlated with immune signatures (Figure 6), thus regulating the TIME of HCC patients. Among the 22 types of immune cells we analyzed (Figures 7, 8), high TGF-β1 expression in HCC patients is positively correlated with regulatory T cells (Tregs), suggesting that high level of TGF-β1 may activate Tregs to suppress antitumor immunity by inhibiting the killing of HCC cells by antigen-specific CD8+ T cells, leading to poor prognosis (30, 37). On the other hand, the negative connection between TGF-β1 expression in HCC cohorts with γδ T cells (Figure 8) may indicate that highly expressed TGF-β1 reduce the number of γδ T cells or suppress the activity of γδ T cells, resulting in more frequent recurrence in HCC patients and poor prognosis (38). Taken together, TGF-β1 can be a promising candidate for immunotherapy in patients with HCC through Tregs and γδ T cells (39–42).
CONCLUSION

To summarize, we performed a systemic bioinformatic analysis based on the RNA-seq datasets of HCC cohorts from TCGA and demonstrated that TGF-β1 contributed to HCC progression and poor prognosis via regulating Tregs and γδ T cells to modulate tumor immunity. Development of TGF-β1 inhibitors can then potentially help to treat HCC by inhibiting tumor growth and metastasis.
**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

All experiments with human tissue samples were reviewed and carried out in accordance with the Declaration of Helsinki and the guidelines of the Ethics Committee of the First Affiliated Hospital of China Medical University (License number 2021–463-2). Informed consents were obtained from all patients. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

XJ and YLL designed the study. YLL was supported by the grant. XJ, YBL and JL wrote the manuscript. XJ and SZ performed the
literature search and collected data for the manuscript. XJ, SZ, NW, and LG analyzed the data and performed the experiments. CS edited the figures and tables. CS and YBL revised the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by the Shenyang Science and Technology Program of 2021 (project number 21-173-9-56) from Shenyang Science and Technology Bureau.

**REFERENCES**

1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. *Nat Rev Gastroenterol Hepatol* (2019) 16:589–604. doi: 10.1038/s41573-019-0188-y
2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular Carcinoma. *Nat Rev Dis Primers* (2021) 7:6. doi: 10.1038/s41575-020-02240-3
3. Liu Y, Guo J, Huang L. Modulation of Tumor Microenvironment for Immunotherapy: Focus on Nanomaterial-Based Strategies. *Theranostics* (2020) 10:3099–117. doi: 10.7150/thno.42998
4. Pinato DJ, Guerra N, Fessas P, Murphy R, Mineo T, Mauri FA, et al. Immune-Based Therapies for Hepatocellular Carcinoma. *Oncogene* (2020) 39:3620–37. doi: 10.1038/s41388-020-1249-9
5. Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. *Immunity* (2020) 52:17–35. doi: 10.1016/j.immuni.2019.12.011
6. Battle E, Massague J. Transforming Growth Factor-Beta Signaling in Immunity and Cancer. *Immunity* (2019) 50:924–40. doi: 10.1016/j.immuni.2019.03.024
7. Hinck AP, Mueller TD, Springer TA. Structural Biology and Evolution of the TGF-Beta Family. *Cold Spring Harb Perspect Biol* (2016) 8:a022103. doi: 10.1101/cshperspect.a022103
8. de Caestecker MP, Piek E, Roberts AB. Role of Transforming Growth Factor-Beta Signaling in Cancer. *J Natl Cancer Inst* (2000) 92:1388–402. doi: 10.1093/jnci/92.17.1388
9. Derynck R, Turley SJ, Akhurst RJ. TGFbeta Biology in Cancer Progression and Immuno-Metastasis. *Nat Rev Clin Oncol* (2011) 8:73. doi: 10.1038/nrclinonc.2011.12
10. Gonzalez-Sanchez E, Vaquero J, Fernandez-Barrena MG, Lasarte JI, Avila MA, Sarobe P, et al. The TGF-Beta Pathway: A Pharmacological Target in Hepatocellular Carcinoma? *Cancers (Basel)* (2021) 13(13):3248. doi: 10.3390/cancers13133248
11. Massague J. TGFbeta in Cancer. *Cell* (2008) 134:215–30. doi: 10.1016/j.cell.2008.07.001
12. Seoane J, Gomis RR. TGF-Beta Family Signaling in Tumor Suppression and Cancer Progression. *Cold Spring Harb Perspect Biol* (2017) 9:a022277.
13. Gupta D, Singh N, Sahu DK. TGF-Beta Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma. *Cancer Growth Metastasis* (2014) 71:–8. doi: 10.4137/CGM.S14205
14. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahim-Kalan A, Jeymand M, et al. Tumor Microenvironment Complexity and Therapeutic Implications at a Glance. *Cell Commun Signal* (2020) 18:59. doi: 10.1186/s12964-020-00350-4
15. Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, et al. Role of Tumor Microenvironment in Tumorogenesis. *J Cancer* (2017) 8:761–73. doi: 10.7150/jca.17648
16. Roth GS, Decaens T. Liver Immunotolerance and Hepatocellular Carcinoma: Patho-Physiological Mechanisms and Therapeutic Perspectives. *Eur J Cancer* (2017) 87:101–12. doi: 10.1016/j.ejca.2017.10.010

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.861601/full#supplementary-material

**Supplementary Figure 1** | Confirmation of prognosis model. Lasso regression analysis was implemented to reduce model complexity and prevent over-fitting, and the obtained coefficients as shown in Figure 1C was used to calculate the risk score (A) and survival time in years (B, C). Principal Component Analysis (PCA) was applied to further validate the effectiveness of the prognosis model and to clarify the difference between the two groups (high risk and low risk) using package ggpubr.
Carcinoma Patients Treated With Sorafenib. *Clin Cancer Res* (2015) 21:3678–84. doi: 10.1158/1078-0432.CCR-14-1954

32. Ji F, Fu SJ, Shen SL, Zhang LJ, Cao QH, Li SQ, et al. The Prognostic Value of Combined TGF-Beta1 and ELF in Hepatocellular Carcinoma. *BMC Cancer* (2015) 15:116. doi: 10.1186/s12885-015-1127-y

33. Poniatowski LA, Wojdasiewicz P, Gasik R, Szuksiewicz D. Transforming Growth Factor Beta Family: Insight Into the Role of Growth Factors in Regulation of Fracture Healing Biology and Potential Clinical Applications. *Mediators Inflamm* (2015) 2015:137823. doi: 10.1155/2015/137823

34. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-Beta - an Excellent Servant But a Bad Master. *J Transl Med* (2012) 10:183. doi: 10.1186/1479-5876-10-183

35. Hayashi H, Sakai T. Biological Significance of Local TGF-Beta Activation in Liver Diseases. *Front Physiol* (2012) 3:32. doi: 10.3389/fphys.2012.00012

36. Lin RL, Zhao LJ. Mechanistic Basis and Clinical Relevance of the Role of Transforming Growth Factor-Beta in Cancer. *Cancer Biol Med* (2015) 12:385–93. doi: 10.7497/j.issn.2095-3941.2015.0015

37. Wang Y, Liu T, Tang W, Deng B, Chen Y, Zhu J, et al. Hepatocellular Carcinoma Cells Induce Regulatory T Cells and Lead to Poor Prognosis via Production of Transforming Growth Factor-Beta1. *Cell Physiol Biochem* (2016) 38:306–18. doi: 10.1159/000438631

38. Cai XY, Wang JX, Yi Y, He HW, Ni XC, Zhou J, et al. Low Counts of Gammadelta T Cells in Peritumoral Liver Tissue are Related to More Frequent Recurrence in Patients With Hepatocellular Carcinoma After Curative Resection. *Asian Pac J Cancer Prev* (2014) 15:775–80. doi: 10.7314/apjcp.2014.15.2.775

39. Tian W, Ma J, Shi R, Ren C, He J, Zhao H. Gammadelta T Cell-Mediated Individualized Immunotherapy for Hepatocellular Carcinoma Considering Clinopathological Characteristics and Immunosuppressive Factors. *Oncol Lett* (2018) 15:5433–42. doi: 10.3892/ol.2018.8026

40. Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cancer Immunotherapy With Gammadelta T Cells: Many Paths Ahead of Us. *Cell Mol Immunol* (2020) 17:925–39. doi: 10.1038/s41423-020-0504-x

41. Langhans B, Nischalke HD, Kramer B, Dold L, Lutz P, Mohr R, et al. Role of Regulatory T Cells and Checkpoint Inhibition in Hepatocellular Carcinoma. *Cancer Immunol Immunother* (2019) 68:2055–66. doi: 10.1007/s00262-019-02427-4

42. Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. *Front Immunol* (2021) 12:643310. doi: 10.3389/fimmu.2021.643310

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Jin, Zhang, Guan, Shao, Liu and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.